5D Library › Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics · 中文

Chapter 3. Coupling Kinetics to Effect: The Perceptual Threshold Is Not a Number

The effect compartment

Plasma concentration and effect are not synchronous: the peak effect usually comes later than the peak concentration, and at the same concentration the effect differs on the way up and on the way down. The standard way to handle this is an effect-compartment model.

Evidence

The effect compartment (methodological primary sources). In 1979 Sheiner and colleagues proposed modelling pharmacokinetics and pharmacodynamics simultaneously, introducing a notional “effect compartment” exchanging with plasma at a first-order rate ke0k_{e0} to account for the lag between effect and concentration (Sheiner et al. 1979). Holford and Sheiner subsequently set out the clinical application of dose-effect relationships systematically (Holford and Sheiner 1981). This is among the most standard tools in pharmacology.

dCedt=ke0(Cp−Ce),E=(Ce/EC50)h1+(Ce/EC50)h.\frac{dC_e}{dt} = k_{e0}\,(C_p – C_e), \qquad E = \frac{(C_e/EC_{50})^h}{1 + (C_e/EC_{50})^h}.

Calculation

# Chapter 3. The effect compartment, and why the time course of an effect is
# not the time course of a concentration. A plasma concentration Cp drives a
# notional effect-site concentration Ce through a first-order link:
#   dCe/dt = ke0 (Cp - Ce)
# and the effect follows the Hill relation of p01 applied to Ce. The
# consequence is
# hysteresis: plotting effect against plasma concentration traces a loop, not
# a curve, and the peak effect lags the peak concentration. The lag is set by
# ke0, which is estimated only by fitting effect data and cannot be obtained
# from concentrations alone. Dimensionless throughout; Cp here is the
# active-species curve of p02.
import math

DT, T_END = 0.002, 16.0
KEL = math.log(2.0)
KA_LOSS = 0.05

def plasma(D=1.0, Km=0.3, Vmax=1.0):
    A, P, out = D, 0.0, []
    for i in range(int(T_END / DT)):
        conv = Vmax * A / (Km + A)
        A = max(0.0, A + DT * (-conv - KA_LOSS * A))
        P = max(0.0, P + DT * (conv - KEL * P))
        out.append(P)
    return out

def effect_site(cp, ke0):
    Ce, out = 0.0, []
    for v in cp:
        Ce += DT * ke0 * (v - Ce)
        out.append(Ce)
    return out

def hill(c, ec50=0.35, h=1.3):
    if c <= 0:
        return 0.0
    r = (c / ec50) ** h
    return r / (1.0 + r)

def summarise(series):
    k = max(range(len(series)), key=lambda i: series[i])
    return series[k], (k + 1) * DT

if __name__ == "__main__":
    cp = plasma()
    cmax, tmax = summarise(cp)
    print(
        "Active-species (plasma) curve: Cmax = {:.4f} at t = {:.2f}".format(
            cmax, tmax
        )
    )
    print("Time unit = elimination half-life of the active species.\n")
    print("   ke0     Ce,max   t(Ce,max)   lag    Emax     t(Emax)   lag")
    for ke0 in (10.0, 3.0, 1.0, 0.3, 0.1):
        ce = effect_site(cp, ke0)
        e = [hill(v) for v in ce]
        cem, cet = summarise(ce)
        em, et = summarise(e)
        print("   {:5.1f} {:8.4f} {:10.2f} {:7.2f} {:8.4f} {:9.2f} {:6.2f}"
              .format(ke0, cem, cet, cet - tmax, em, et, et - tmax))

    print(
        "\nAs ke0 falls, the effect-site peak is lower and later: at ke0 = 10"
        " the lag"
    )
    print(
        "is almost nothing, at ke0 = 0.1 it is more than a half-life. The"
        " plasma"
    )
    print(
        "curve is IDENTICAL in every row. So the shape of the effect over"
        " time is"
    )
    print(
        "not a property of the pharmacokinetics; it is a property of ke0,"
        " which has"
    )
    print(
        "to be fitted to effect measurements and cannot be read off"
        " concentrations."
    )

    print("\nHysteresis: effect against plasma concentration, ke0 = 0.3,")
    print("on the way up and on the way down.")
    ce = effect_site(cp, 0.3)
    e = [hill(v) for v in ce]
    peak_i = max(range(len(cp)), key=lambda i: cp[i])
    print("   Cp      effect (rising)   effect (falling)")
    for target in (0.05, 0.10, 0.20, 0.30):
        up = next((i for i in range(peak_i) if cp[i] >= target), None)
        dn = next(
            (i for i in range(len(cp) - 1, peak_i, -1) if cp[i] >= target),
            None,
        )
        if up is not None and dn is not None:
            print("   {:6.3f} {:17.4f} {:18.4f}".format(target, e[up], e[dn]))
    print(
        "\n   At the same plasma concentration the effect is larger on the"
        " way down"
    )
    print(
        "   than on the way up. Any attempt to read a concentration-effect"
        " curve"
    )
    print(
        "   from paired samples without modelling the lag will therefore"
        " produce a"
    )
    print("   loop and, if the loop is averaged away, a wrong EC50.")

    print(
        "\nWhat this means for the word 'sub-perceptual'. Suppose the"
        " threshold of"
    )
    print("noticing sits at an effect of 0.25. Time spent above it:")
    for ke0 in (10.0, 1.0, 0.3, 0.1):
        ce = effect_site(cp, ke0)
        e = [hill(v) for v in ce]
        above = sum(1 for v in e if v >= 0.25) * DT
        print(
            "   ke0 = {:5.1f}: {:.2f} half-lives above the threshold, peak"
            " effect {:.3f}".format(ke0, above, max(e))
        )
    print(
        "\n   The result is not a graded one. For ke0 of 0.3 and above the"
        " same"
    )
    print(
        "   exposure sits above the threshold for close to four"
        " half-lives; at"
    )
    print(
        "   ke0 = 0.1 it never reaches the threshold at all, because the"
        " effect-site"
    )
    print(
        "   peak (0.162) falls short of 0.25. One unmeasured parameter"
        " therefore"
    )
    print(
        "   decides between 'clearly noticeable for most of a day' and 'never"
    )
    print(
        "   noticeable', at an identical plasma curve. 'Sub-perceptual' is"
        " not a"
    )
    print(
        "   statement about an amount; p05 shows it is not even a statement"
        " about"
    )
    print("   one person.")
# Active-species (plasma) curve: Cmax = 0.4972 at t = 1.34
# Time unit = elimination half-life of the active species.
#
#    ke0     Ce,max   t(Ce,max)   lag    Emax     t(Emax)   lag
#     10.0   0.4947       1.44    0.10   0.6106      1.44   0.10
#      3.0   0.4704       1.68    0.34   0.5949      1.68   0.34
#      1.0   0.3740       2.18    0.84   0.5215      2.18   0.84
#      0.3   0.2120       3.06    1.72   0.3426      3.06   1.72
#      0.1   0.0989       4.17    2.83   0.1621      4.17   2.83
#
# As ke0 falls, the effect-site peak is lower and later: at ke0 = 10 the lag
# is almost nothing, at ke0 = 0.1 it is more than a half-life. The plasma
# curve is IDENTICAL in every row. So the shape of the effect over time is
# not a property of the pharmacokinetics; it is a property of ke0, which has
# to be fitted to effect measurements and cannot be read off concentrations.
#
# Hysteresis: effect against plasma concentration, ke0 = 0.3,
# on the way up and on the way down.
#    Cp      effect (rising)   effect (falling)
#     0.050            0.0002             0.2684
#     0.100            0.0013             0.3166
#     0.200            0.0087             0.3424
#     0.300            0.0277             0.3329
#
#    At the same plasma concentration the effect is larger on the way down
#    than on the way up. Any attempt to read a concentration-effect curve
#    from paired samples without modelling the lag will therefore produce a
#    loop and, if the loop is averaged away, a wrong EC50.
#
# What this means for the word 'sub-perceptual'. Suppose the threshold of
# noticing sits at an effect of 0.25. Time spent above it:
#    ke0 =  10.0: 3.35 half-lives above the threshold, peak effect 0.611
#    ke0 =   1.0: 3.88 half-lives above the threshold, peak effect 0.522
#    ke0 =   0.3: 3.83 half-lives above the threshold, peak effect 0.343
#    ke0 =   0.1: 0.00 half-lives above the threshold, peak effect 0.162
#
#    The result is not a graded one. For ke0 of 0.3 and above the same
#    exposure sits above the threshold for close to four half-lives; at
#    ke0 = 0.1 it never reaches the threshold at all, because the effect-site
#    peak (0.162) falls short of 0.25. One unmeasured parameter therefore
#    decides between 'clearly noticeable for most of a day' and 'never
#    noticeable', at an identical plasma curve. 'Sub-perceptual' is not a
#    statement about an amount; p05 shows it is not even a statement about
#    one person.

The whole content of the first table is that the plasma curve is identical in every row while the height and timing of the effect peak vary a great deal with ke0k_{e0}. At ke0=10k_{e0} = 10 the lag is almost nothing; at ke0=0.1k_{e0} = 0.1 it is 2.83 half-lives, and the peak is about a quarter of the former.

So

the time course of an effect is not a property of the pharmacokinetics but a property of ke0k_{e0}.

And ke0k_{e0} can only be fitted to effect data; it cannot be read off concentration data. This has a sharp consequence for the book’s subject, in the program’s last section: taking the perceptual threshold to sit at an effect of 0.25, the same plasma curve spends nearly four half-lives above the threshold when ke0≥0.3k_{e0} \ge 0.3 and never crosses it when ke0=0.1k_{e0} = 0.1 (peak effect 0.162). One unmeasured parameter decides between “clearly noticeable for most of a day” and “not noticeable at all”.

The hysteresis loop

The program’s second section gives the other face of the same model: at the same plasma concentration the effect on the way down is far larger than on the way up (0.3166 against 0.0013 at Cp=0.10C_p = 0.10). A plot of effect against concentration is not a curve but a loop.

The hysteresis loop of effect against plasma concentration (k_{e0} = 0.3). Arrows show the direction of time. At the same plasma concentration, the effect on the falling limb (upper branch) is far larger than on the rising limb (lower branch). Fitting paired concentration-effect samples as a single curve yields a meaningless EC_{50}.

This has a practical consequence: any attempt to read a concentration-effect curve directly from paired plasma and effect samples will, if it does not model the lag, produce a loop; and if the loop is averaged away, the resulting EC50EC_{50} is wrong. Volume 34 discussed the fitting of psychophysical functions; the problem here is of the same kind with one extra dimension, time.

“Sub-perceptual” is a population distribution

Chapter 1 showed that the receptor supplies no threshold and that only perception can. This section shows that what perception supplies is not a number either.

Between an amount and a person there lie at least two layers of individual variation: the same amount produces different exposures in different people (pharmacokinetic variability), and the same exposure crosses different thresholds of noticing in different people (pharmacodynamic variability).

Calculation

# Chapter 3. "Sub-perceptual" is a distribution across people, not a dose. Two
# sources of variability sit between a dose fraction and whether anyone
# notices anything:
#   (1) pharmacokinetic: exposure per unit dose varies between people
#   (log-normal, CV_pk) (2) pharmacodynamic: the concentration at which a
#   person notices varies (log-normal)
# The program computes, for a range of dose fractions, the proportion of a
# population who would notice an effect, and then asks the design question
# that matters for Chapter 8: at what dose fraction is the proportion noticing
# low enough for a trial to stay blind? Dimensionless; synthetic population;
# fixed seed; standard library only.
import math
import random
from statistics import NormalDist

N = NormalDist()
CV_PK = 0.45        # between-person variability in exposure per unit dose
CV_THR = 0.60       # between-person variability in the noticing threshold
POP = 40000

def lognormal_sigma(cv):
    return math.sqrt(math.log(1.0 + cv * cv))

def proportion_noticing(dose_fraction, rng):
    s_pk = lognormal_sigma(CV_PK)
    s_th = lognormal_sigma(CV_THR)
    hit = 0
    for _ in range(POP):
        exposure = dose_fraction * math.exp(rng.gauss(-s_pk ** 2 / 2, s_pk))
        thresh = math.exp(rng.gauss(-s_th ** 2 / 2, s_th))
        hit += exposure >= thresh
    return hit / POP

def analytic(dose_fraction):
    """Both log-normal with unit median: P(exposure >= threshold) is a normal
    cdf."""
    s = math.sqrt(lognormal_sigma(CV_PK) ** 2 + lognormal_sigma(CV_THR) ** 2)
    return N.cdf(math.log(dose_fraction) / s)

if __name__ == "__main__":
    rng = random.Random(5204)
    print("Between-person CV: exposure {:.0%}, noticing threshold {:.0%}."
          .format(CV_PK, CV_THR))
    print(
        "Dose fraction 1.0 is defined as the population MEDIAN noticing"
        " exposure.\n"
    )
    print("   dose fraction   proportion noticing (simulated)   (analytic)")
    for d in (0.05, 0.10, 0.15, 0.20, 0.30, 0.50, 1.00):
        print("   {:13.2f} {:32.4f} {:12.4f}"
              .format(d, proportion_noticing(d, rng), analytic(d)))

    print(
        "\nThere is no dose fraction at which the proportion is zero. At one"
        " tenth of"
    )
    print(
        "the median noticing exposure, {:.1%} of people still notice"
        " something; at".format(analytic(0.10))
    )
    print(
        "one fifth, {:.1%} do. A blind that depends on nobody noticing"
        " cannot be".format(analytic(0.20))
    )
    print(
        "achieved by lowering the amount; it can only be made imperfect to a"
        " known"
    )
    print(
        "degree, which is why Chapter 8 MEASURES the blind rather than"
        " assuming it."
    )

    print(
        "\nThe design question: what proportion noticing can a trial"
        " tolerate? If a"
    )
    print(
        "fraction f of participants correctly identify their allocation and"
        " their"
    )
    print(
        "expectancy contributes an effect of size g (in SD units) while the"
        " drug"
    )
    print(
        "itself contributes nothing, the observed between-arm difference is"
        " about"
    )
    print("f * g. For an observed 0.20 SD difference to be pure expectancy:")
    print("   proportion noticing f   required expectancy effect g (SD)")
    for f in (0.05, 0.10, 0.20, 0.40, 0.60):
        print("   {:21.2f} {:38.2f}".format(f, 0.20 / f))
    print(
        "\n   At f = 0.40 an expectancy effect of 0.50 SD would suffice,"
        " which is"
    )
    print(
        "   well within the range reported for open-label expectancy"
        " manipulations."
    )
    print(
        "   At f = 0.05 it would need 4.0 SD, which is not plausible. So the"
        " blind"
    )
    print(
        "   integrity measurement is not a formality: it decides whether an"
        " observed"
    )
    print(
        "   difference of this size can be explained without any drug effect"
        " at all."
    )

    print(
        "\nInverting: the dose fraction at which a given proportion notices."
    )
    s = math.sqrt(lognormal_sigma(CV_PK) ** 2 + lognormal_sigma(CV_THR) ** 2)
    print("   target proportion   dose fraction")
    for p in (0.02, 0.05, 0.10, 0.25, 0.50):
        print("   {:17.2f} {:14.4f}".format(p, math.exp(N.inv_cdf(p) * s)))
    d02 = math.exp(N.inv_cdf(0.02) * s)
    print(
        "\n   Reaching 2 % noticing requires about {:.0%} of the median"
        " noticing".format(d02)
    )
    print(
        "   exposure - a fourfold reduction, not the hundredfold that the"
        " word"
    )
    print(
        "   'micro' suggests. Note also how flat this is: between 2 % and"
        " 25 %"
    )
    print(
        "   noticing there is only a factor of {:.1f} in exposure, so a"
        " schedule".format(math.exp(N.inv_cdf(0.25) * s) / d02)
    )
    print(
        "   intended to stay below the threshold has very little margin."
        " Whether"
    )
    print(
        "   anything else survives at that exposure is exactly the open"
        " question,"
    )
    print(
        "   and Chapter 4 shows why the receptor argument does not settle it."
    )
# Between-person CV: exposure 45%, noticing threshold 60%.
# Dose fraction 1.0 is defined as the population MEDIAN noticing exposure.
#
#    dose fraction   proportion noticing (simulated)   (analytic)
#             0.05                           0.0000       0.0000
#             0.10                           0.0008       0.0005
#             0.15                           0.0045       0.0034
#             0.20                           0.0138       0.0109
#             0.30                           0.0505       0.0430
#             0.50                           0.1847       0.1615
#             1.00                           0.5379       0.5000
#
# There is no dose fraction at which the proportion is zero. At one tenth of
# the median noticing exposure, 0.1% of people still notice something; at
# one fifth, 1.1% do. A blind that depends on nobody noticing cannot be
# achieved by lowering the amount; it can only be made imperfect to a known
# degree, which is why Chapter 8 MEASURES the blind rather than assuming it.
#
# The design question: what proportion noticing can a trial tolerate? If a
# fraction f of participants correctly identify their allocation and their
# expectancy contributes an effect of size g (in SD units) while the drug
# itself contributes nothing, the observed between-arm difference is about
# f * g. For an observed 0.20 SD difference to be pure expectancy:
#    proportion noticing f   required expectancy effect g (SD)
#                     0.05                                   4.00
#                     0.10                                   2.00
#                     0.20                                   1.00
#                     0.40                                   0.50
#                     0.60                                   0.33
#
#    At f = 0.40 an expectancy effect of 0.50 SD would suffice, which is
#    well within the range reported for open-label expectancy manipulations.
#    At f = 0.05 it would need 4.0 SD, which is not plausible. So the blind
#    integrity measurement is not a formality: it decides whether an observed
#    difference of this size can be explained without any drug effect at all.
#
# Inverting: the dose fraction at which a given proportion notices.
#    target proportion   dose fraction
#                 0.02         0.2368
#                 0.05         0.3155
#                 0.10         0.4071
#                 0.25         0.6231
#                 0.50         1.0000
#
#    Reaching 2 % noticing requires about 24% of the median noticing
#    exposure - a fourfold reduction, not the hundredfold that the word
#    'micro' suggests. Note also how flat this is: between 2 % and 25 %
#    noticing there is only a factor of 2.6 in exposure, so a schedule
#    intended to stay below the threshold has very little margin. Whether
#    anything else survives at that exposure is exactly the open question,
#    and Chapter 4 shows why the receptor argument does not settle it.

The conclusion of the first table is that no dose fraction makes the proportion noticing zero. This is not a matter of parameter choice: the tails of two log-normal distributions necessarily overlap.

The second section translates this into design language. If a proportion ff of participants correctly identify their allocation, and their expectancy contributes an effect of gg standard deviations, the apparent between-arm difference is about f×gf \times g. To explain an observed difference of 0.20 SD by expectancy alone: at f=0.40f = 0.40 one needs only g=0.50g = 0.50, a magnitude commonly seen in open-label expectancy manipulations; at f=0.05f = 0.05 one needs g=4.0g = 4.0, which is not credible. Measuring blind integrity is therefore not a formality — it decides whether an observed difference of this size can be explained away with no pharmacological effect at all.

The third section inverts the calculation and notes something that matters for design: between 2 % and 25 % noticing there is only a 2.6-fold margin in exposure. An arrangement intended to stay below the threshold has almost no room.

Note

Consequences for Chapter 8. A blind cannot be secured by lowering the exposure. Chapter 8 therefore (i) measures blind integrity and powers the trial to detect a departure from chance, (ii) pre-specifies the belief-stratified contrast as a key secondary analysis, and (iii) writes a broken blind into the decision rule as a qualifier. There is systematic-review evidence that lack of participant blinding biases results (Hróbjartsson et al. 2014); the book’s response is to measure it rather than to assume it away.

Hypothesis · not established

The author’s hypothesis (not established): in double-blind trials of this class of compound, the proportion guessing allocation correctly rises monotonically with the exposure in the active condition, and at any exposure producing a detectable objective effect the proportion guessing correctly is significantly above chance. What would show it to be wrong: in a pre-registered double-blind dose-response study, finding an exposure at which the confidence interval for improvement in a pre-specified objective outcome relative to placebo excludes zero while the confidence interval for the Bang blinding index (Bang, Ni, and Davis 2004) includes zero.

Summary

The effect compartment is a standard pharmacological tool, and it yields a conclusion central to this book: the time course of an effect is a property of ke0k_{e0} rather than of the pharmacokinetics. Under an identical plasma curve, lowering ke0k_{e0} from 0.3 to 0.1 changes “does it cross the perceptual threshold” from “nearly four half-lives above it” to “never”, and ke0k_{e0} can only be fitted to effect data. The same model yields the hysteresis loop: at a given plasma concentration the falling limb shows far more effect than the rising limb, so a concentration-effect fit that does not model the lag gives a wrong EC50EC_{50}. Finally, “sub-perceptual” is a population distribution rather than a dose: in a population with individual variation in both exposure and threshold, no dose fraction makes the proportion noticing zero, and between 2 % and 25 % noticing there is only a 2.6-fold margin. To explain an observed 0.20 SD difference by expectancy alone requires only a 0.50 SD expectancy effect at a 40 % correct-guess rate, so blind integrity must be measured.

References

Bang, Heejung, Liyun Ni, and Clarence E. Davis. 2004. “Assessment of Blinding in Clinical Trials.” Controlled Clinical Trials 25 (2): 143–56. https://doi.org/10.1016/j.cct.2003.10.016.
Holford, Nicholas H. G., and Lewis B. Sheiner. 1981. “Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models.” Clinical Pharmacokinetics 6 (6): 429–53. https://doi.org/10.2165/00003088-198106060-00002.
Hróbjartsson, Asbjørn, Frida Emanuelsson, Ann Sofia Skou Thomsen, Jørgen Hilden, and Stig Brorson. 2014. “Bias Due to Lack of Patient Blinding in Clinical Trials: A Systematic Review of Trials Randomizing Patients to Blind and Nonblind Sub-Studies.” International Journal of Epidemiology 43 (4): 1272–83. https://doi.org/10.1093/ije/dyu115.
Sheiner, Lewis B., Donald R. Stanski, Samuel Vozeh, Ronald D. Miller, and Jerry Ham. 1979. “Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics: Application to d-Tubocurarine.” Clinical Pharmacology and Therapeutics 25 (3): 358–71. https://doi.org/10.1002/cpt1979253358.

Fan, Y. (2026). Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics: From Michaelis–Menten Kinetics of Prodrug Deacetylation and Whole-Brain Connectivity Entropy to the Microdose Tolerance Ratchet, with a Textual Examination of the Dose Boundary in the Classical Materia Medica [亚知觉色胺药代动力学、5-HT2A 受体脱敏与神经可塑性窗口的生物数学模型] (Version 1.0.0). 5D Library. https://doi.org/10.5281/zenodo.24019347 · Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).